Company: SINT
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024040
Chunk: 4

Company: Sintx Technologies, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 8
Chunk 4
---
 basis, the impact on the Company will be material and adverse.

    8

The
Board of Directors, together with management, is performing an ongoing evaluation of the Company’s business strategy and focus.

The
Company’s strategic emphasis is focused on utilizing its technology in making advancements in the biomedical sector.
Historically engaged in both industrial and biomedical applications, SINTX has prioritized the development and commercialization of
innovative medical devices, leveraging its expertise in advanced ceramics and biomaterials. This renewed focus aligns with a
commitment to improving patient outcomes through the creation of products designed for surgical, orthopedic, and other specialized
medical applications. We are concentrating our resources on high-growth areas within the healthcare sector where our proprietary
materials and technologies—such as silicon nitride—provide a distinct competitive advantage due to their unique
strength, durability, and biocompatibility.

Through
this transformation, SINTX’s aim is to deliver meaningful innovations to the medical community. Our current research and development
pipeline is centered on medical-grade devices that incorporate antimicrobial properties, enhanced imaging capabilities, and durability
under physiological conditions, which are critical for orthopedic implants, spinal fusion devices, and other surgical tools. As we transition
our focus away from industrial applications, we anticipate this strategic shift will enable us to better serve the medical sector, address
critical unmet needs, and position SINTX as a leading provider in the medical device market. By focusing on partnerships and collaborations
with healthcare institutions and industry leaders, SINTX is positioned to expand its footprint in the medical device sector and drive
shareholder value through sustainable, high-impact innovations.

On
August 8, 2024, the Board of Directors approved a plan to implement a Company-wide reduction in the workforce. This decision was part
of the Company’s ongoing strategic review of its operations aimed at improving operational efficiency and reducing costs.

On
August 12, 2024, the Board of Directors approved a plan to cease efforts to make the armor plant operational. This decision was made
to streamline operations and focus on core business areas that align with the Company’s long-term strategic goals. The armor plant
has not been fully operational since the acquisition of the armor equipment in July 2021 and has been completely shut down since October
2023 due to the malfunctioning of the sintering furnace. In connection with this decision, the Company incurred an impairment charge
of approximately $4.6 million during the year ended December